A potent and selective quinoxalinone-based STK33 inhibitor does not show synthetic lethality in KRAS-dependent cells

ACS Medicinal Chemistry Letters

Volumn 3, Issue 12, 2012, Pages 1034-1038

  Weïwer, Michel ^a   Spoonamore, James ^a   Wei, Jingqiang ^a   Guichard, Boris ^a   Ross, Nathan T ^a   Masson, Kristina ^a   Silkworth, Whitney ^a   Dandapani, Sivaraman ^a   Palmer, Michelle ^a   Scherer, Christina A ^a   Stern, Andrew M ^a   Schreiber, Stuart L ^a,b   Munoz, Benito ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

KRAS synthetic lethality; MLPCN probe; STK33 inhibitor

Indexed keywords

AURORA B KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE; MESSENGER RNA; ML 281; PROTEIN SERINE THREONINE KINASE; QUINOXALINE DERIVATIVE; RECOMBINANT ENZYME; SERINE THREONINE KINASE STK33; SERINE THREONINE KINASE STK33 INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; IC 50; LETHALITY; ONCOGENE K RAS; PRIORITY JOURNAL; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION;

EID: 84871217012     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300246r     Document Type: Article

References (10)

1. Harvey, J. J. An unidentified virus which causes the rapid production of tumours in mice Nature 1964, 204, 1104-1105
2. Kirsten, W. H.; Mayer, L. A. Morphological responses to a murine erythroblastosis virus J. Natl. Cancer Inst. 1967, 39 (2) 311-335
3. Barbacid, M. Ras genes Annu. Rev. Biochem. 1987, 56, 779-827
4. Bos, J. L. Ras oncogenes in human cancer: A review Cancer Res. 1989, 49 (17) 4682-4689
5. Malumbre, M.; Barbacid, M. Ras oncogenes: The first 30 years Nat. Rev. Cancer 2003, 3 (6) 459-465
6. Yang, W. S.; Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells Chem. Biol. 2008, 15 (3) 234-245
7. Scholl, C.; Frohling, S.; Dunn, I. F.; Schinzel, A. C.; Barbie, D. A.; Kim, S. Y.; Silver, S. J.; Tamayo, P.; Wadlow, R. C.; Ramaswamy, S.; Dohner, K.; Bullinger, L.; Sandy, P.; Boehm, J. S.; Root, D. E.; Jacks, T.; Hahn, W. C.; Gilliland, D. G. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells Cell 2009, 137, 821-834
8. Babij, C.; Zhang, Y.; Kurzeja, R. J.; Munzli, A.; Shehabeldin, A.; Fernando, M.; Quon, K.; Kassner, P. D.; Ruefli-Brasse, A. A.; Watson, V. J.; Fajardo, F.; Jackson, A.; Zondlo, J.; Sun, Y.; Ellison, A. R.; Plewa, C. A.; San Miguel, T.; Robinson, J.; McCarter, J.; Schwandner, R.; Judd, T.; Carnahan, J.; Dussault, I. STK33 kinase activity is nonessential in KRAS-dependent cancer cells Cancer Res. 2011, 71 (17) 5818-5826
9. Luo, T.; Masson, K.; Jaffe, J. D.; Silkworth, W.; Ross, N. T.; Scherer, C.; Scholl, C.; Fröhling, S.; Carr, S. A.; Schreiber, S. L.; Stern, A. M.; Golub, T. R. STK33 small-molecule kinase inhibitors do not kill KRAS mutant cancer cells Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (8) 2860-2865
10. Hanks, S.; Hunter, T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification FASEB J. 1995, 9 (8) 576-596